Home-Based Wearable Therapy for Overactive Bladder: A Clinical Trial Investigating a Smart Patch System

This clinical trial is investigating an innovative wearable device called the Confidanz Smart Patch System for managing overactive bladder (OAB) and urinary incontinence symptoms. The study is specifically designed for patients who have been diagnosed with idiopathic overactive bladder by qualified specialists. This means the condition has no identifiable underlying cause, which is common in many OAB cases.

The trial is particularly significant because it offers a home-based treatment approach, allowing participants to administer their therapy through a mobile application while under clinical supervision. This represents a major advancement in bladder management, as traditional treatments often require frequent clinic visits that can be inconvenient and time-consuming for patients. The wearable microneedle system works by delivering percutaneous tibial nerve stimulation, a therapy that has shown promise in regulating bladder function through neurological pathways.

Participants in this randomized, single-blinded study will be assigned to either the active treatment group or a sham control group in a 3:1 ratio. Those in the treatment arm will receive actual nerve stimulation, while the control group will use identical equipment without active stimulation. This careful study design helps researchers determine whether any improvements are truly due to the treatment itself rather than placebo effects. The trial will enroll up to 40 adult participants who will undergo 12 weeks of weekly treatments, each consisting of a 30-minute stimulation session.

Safety monitoring is a crucial aspect of this investigation, with researchers carefully tracking any adverse events throughout the study period. Participants will complete comprehensive assessments including 3-day bladder diaries, standardized questionnaires about their incontinence symptoms, quality of life measures, and pain scales. These evaluations will occur at baseline, 6 weeks, and 12 weeks to measure potential improvements in bladder control and overall wellbeing.

The importance of this research extends beyond the immediate study participants. Overactive bladder affects millions of people worldwide, significantly impacting quality of life, sleep patterns, social activities, and emotional wellbeing. Many current treatment options, including medications, behavioral therapies, and more invasive procedures, come with limitations such as side effects, incomplete effectiveness, or practical challenges. This wearable technology represents a promising alternative that could potentially offer non-invasive, convenient, and effective symptom management.

For patients and caregivers considering participation, it's important to understand the eligibility requirements. The study excludes individuals with certain medical conditions including urinary tract infections, pregnancy, specific neurological disorders, recent botulinum toxin treatments, or implanted medical devices. These exclusions help ensure participant safety and maintain the integrity of the research findings. The investigation is scheduled to run from August 2025 through January 2026, with careful monitoring by clinical researchers throughout the study period.

Research in bladder health and incontinence management continues to evolve, with increasing recognition of how these conditions affect overall quality of life. Studies like this one contribute valuable knowledge about innovative treatment approaches that could potentially help millions of people manage their symptoms more effectively. The development of home-based therapies represents an important shift toward patient-centered care that respects individuals' time, autonomy, and comfort while still maintaining medical oversight and safety standards.